Amplexa Genetics A/S is a Danish A/S based in Odense C, operating in the Engineering activities and related technical consultancy sector. Incorporated in 2006, the company has 13 employees and reported a gross profit of DKK 4.0m in its latest annual filing.
| Gross profit | 4M DKK | +18% |
| EBITDA | -1.4M DKK | +82% |
| Net profit | -1.6M DKK | +86% |
| Total assets | 2.9M DKK | -21% |
| Equity | -10.3M DKK | -18% |
| Employees | 13 | — |
In its most recent annual report (2025), Amplexa Genetics A/S reported a gross profit of DKK 4.0m, an increase of 18% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of DKK 1.6m, and the EBITDA margin stood at -33.9%.
At the end of 2025, current assets covered short-term debt 1.9 times.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross profit | 4,009 | 3,399 | 3,225 | 5,495 | 20,278 |
| Staff expenses | -5,368 | -6,405 | -6,639 | -7,228 | -9,031 |
| EBITDA | -1,359 | -7,483 | -3,414 | -1,733 | 11,247 |
| Depreciation & amort. | -371 | -480 | -649 | -818 | -810 |
| EBIT | -1,730 | -7,963 | -4,063 | -2,551 | 10,437 |
| Net financials | -134 | -31 | 17 | -474 | -495 |
| Profit before tax | -1,864 | -7,994 | -4,046 | -3,025 | 9,943 |
| Tax | -281 | 3,115 | -915 | -742 | -2,386 |
| Net profit | -1,583 | -11,108 | -3,131 | -2,282 | 12,328 |
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 2,892 | 3,647 | 14,976 | 12,284 | 18,363 |
| Equity | -10,313 | -8,730 | 2,378 | -14,491 | -12,208 |
| Long-term debt | 11,810 | 10,610 | 10,610 | 25,610 | 26,260 |
| Short-term debt | 1,396 | 1,767 | 1,987 | 1,165 | 4,311 |
| Total debt | 13,206 | 12,377 | 12,597 | 26,775 | 30,571 |
28 financial ratios from the latest filing, each graded against companies in the same industry.
Net profit as a percentage of total assets — the return generated on the capital employed.
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA relative to debt — how much operating earnings are available to service the debt.
The ability to pay the interest on the company's debt out of its earnings.
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
The size of this year's increase or decrease in the company's debt.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
The size of this year's increase or decrease in the company's equity.
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PC Founder | Founder | 2006 |
KB Management | Management | 2006 – 2011 |
HA Chief Executive Officer | Chief Executive Officer | 2011 – 2018 |
HH Chief Executive Officer | Chief Executive Officer | 2018 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
ER Board of Directors | Board of Directors | 2011 |
MH Chairman | Chairman | 2026 |
UB Board of Directors | Board of Directors | 2023 |
LM Board of Directors | Board of Directors | 2013 – 2015 |
CS Board of Directors | Board of Directors | 2018 – 2023 |
NC Board of Directors | Board of Directors | 2013 – 2023 |
AS Board of Directors | Board of Directors | 2008 – 2009 |
PM Board of Directors | Board of Directors | 2009 – 2018 |
JD Board of Directors | Board of Directors | 2006 – 2008 |
JJ Chairman | Chairman | 2015 – 2026 |
LA Board of Directors | Board of Directors | 2018 – 2023 |
JK Chairman | Chairman | 2013 – 2015 |
MR Board of Directors | Board of Directors | 2006 – 2010 |
| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Individual | 33.33–49.99% | 33.33–49.99% | 2024 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2024 | |
| Individual | 25–33.32% | 25–33.32% | 2023 | |
| Individual | 20–24.99% | 20–24.99% | 2023 |
| Person | Role here | Other companies |
|---|---|---|
| Ulf Bech Christensen | Board of Directors | 9 companiesMany roles |
| Andras Splidt | Board of Directors | 2 companies |
| Jørn Kildegaard Andersen | Chairman | 2 companies |
| Hans Atli Eli Albinus Dahl | Chief Executive Officer | 1 company |